Ford Motor Company

About: Ford Motor Company is a company organization based out in Dearborn, Michigan, United States. It is known for research contribution in the topics: Internal combustion engine & Clutch. The organization has 36123 authors who have published 51450 publications receiving 855200 citations. The organization is also known as: Ford Motor & Ford Motor Corporation.

Telematics system and method for traction reporting and control in a vehicle

Abstract: In one embodiment, a system and method are provided for detecting a slip condition between a vehicle tire and a road surface, processing contemporaneous vehicle data, such as torque or brake pressure applied, to determine a force of friction, and calculating a coefficient of friction. The coefficient of friction and location of the slip are broadcast to other vehicles driving in the proximity of the slip. The broadcasts may be utilized to notify drivers of slippery driving conditions at or ahead of the vehicle, and/or to limit torque and braking pressure applied to vehicle wheels to enhance traction and avoid slip.

Post-ischemic treatment with erythropoietin or carbamylated erythropoietin reduces infarction and improves neurological outcome in a rat model of focal cerebral ischemia.

Abstract: Background and purpose: Recombinant human erythropoietin (rhEPO; Epoetin-α; PROCRIT™) has been shown to exert neuroprotective and restorative effects in a variety of CNS injury models However, limited information is available regarding the dose levels required for these beneficial effects or the neuronal responses that may underlie them Here we have investigated the dose-response to rhEPO and compared the effects of rhEPO with those of carbamylated rhEPO (CEPO) in a model of cerebral stroke in rats Experimental approach: Rats subjected to embolic middle cerebral artery occlusion (MCAo) were treated with rhEPO or CEPO, starting at 6 h and repeated at 24 and 48 h, after MCAo Cerebral infarct volumes were assessed at 28 days and neurological impairment at 7, 14, 21 and 28 days, post-MCAo Key results: rhEPO at dose levels of 500, 1150 or 5000 IU kg−1 or CEPO at a dose level of 50 μg kg−1 significantly reduced cortical infarct volume and reduced neurologic impairment All doses of rhEPO, but not CEPO, produced a transient increase in haematocrit, while rhEPO and CEPO substantially reduced the number of apoptotic cells and activated microglia in the ischemic boundary region Conclusions and implications: These data indicate that rhEPO and CEPO have anti-inflammatory and anti-apoptotic effects, even with administration at 6 h following embolic MCAo in rats Taken together, these actions of rhEPO and CEPO are likely to contribute to their reduction of neurologic impairment following cerebral ischemia British Journal of Pharmacology (2007) 151, 1377–1384; doi:101038/sjbjp0707285